<!DOCTYPE html>
<html class="no-js" lang="en">
<head>
	<meta charset="UTF-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title>FDA grants traditional approval to Eisai/Biogen Alzheimer’s drug Leqembi - The Zombie Fridge Journal</title>
	<script>(function(d,e){d[e]=d[e].replace("no-js","js");})(document.documentElement,"className");</script>
	<meta name="description" content="July 12 (ZFJ) — The Food and Drug Administration granted traditional approval to Eisai and Biogen’s Leqembi (lecanemab-irmb) 100 mg/mL intravenous injection on July 6. It is the first Alzheimer’s drug to clear this regulatory hurdle and aims to slow the disease’s progression.">
		<meta property="og:title" content="FDA grants traditional approval to Eisai/Biogen Alzheimer’s drug Leqembi" />
<meta property="og:description" content="July 12 (ZFJ) — The Food and Drug Administration granted traditional approval to Eisai and Biogen’s Leqembi (lecanemab-irmb) 100 mg/mL intravenous injection on July 6. It is the first Alzheimer’s drug to clear this regulatory hurdle and aims to slow the disease’s progression." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://theZFJ.github.io/health-and-medicine/2023/fda-traditional-approval-leqembi/" /><meta property="og:image" content="https://theZFJ.github.io/2023/health-and-medicine/leqembiProductPackagingShotMay2023.jpg" /><meta property="og:image" content="https://theZFJ.github.io/2023/health-and-medicine/leqembiEndpoints.jpeg" /><meta property="article:section" content="Health-and-Medicine" />
<meta property="article:published_time" content="2023-07-13T03:07:35-04:00" />
<meta property="article:modified_time" content="2023-07-13T03:07:35-04:00" /><meta property="og:site_name" content="The Zombie Fridge Journal" />


	<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
	<link rel="dns-prefetch" href="//fonts.googleapis.com">
	<link rel="dns-prefetch" href="//fonts.gstatic.com">
	<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700">

	<link rel="stylesheet" href="/css/style.css">
	<link rel="stylesheet" href="/custom.css">

	<link rel="shortcut icon" href="/favicon.ico">
		
<script async src="https://www.googletagmanager.com/gtag/js?id=G-506M1GBBP6"></script>
<script>
var doNotTrack = false;
if (!doNotTrack) {
	window.dataLayer = window.dataLayer || [];
	function gtag(){dataLayer.push(arguments);}
	gtag('js', new Date());
	gtag('config', 'G-506M1GBBP6', { 'anonymize_ip': false });
}
</script>

</head>
<body class="body">
	<div class="container container--outer">
		<header class="header">
	<div class="container header__container">
		
	<div class="logo logo--mixed">
		<a class="logo__link" href="/" title="The Zombie Fridge Journal" rel="home">
			<div class="logo__item logo__imagebox">
					<img class="logo__img" src="/zfjLogo.png">
				</div><div class="logo__item logo__text">
					<div class="logo__title">The Zombie Fridge Journal</div>
					<div class="logo__tagline">Semper serius.</div>
				</div>
		</a>
	</div>
		
<nav class="menu">
	<button class="menu__btn" aria-haspopup="true" aria-expanded="false" tabindex="0">
		<span class="menu__btn-title" tabindex="-1">Menu</span>
	</button>
	<ul class="menu__list">
		<li class="menu__item">
			<a class="menu__link" href="/about/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">About</span>
				
			</a>
		</li>
		<li class="menu__item">
			<a class="menu__link" href="/categories/domestic-affairs/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">Domestic Affairs</span>
				
			</a>
		</li>
		<li class="menu__item">
			<a class="menu__link" href="/categories/foreign-affairs/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">Foreign Affairs</span>
				
			</a>
		</li>
		<li class="menu__item">
			<a class="menu__link" href="/categories/business/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">Business</span>
				
			</a>
		</li>
		<li class="menu__item">
			<a class="menu__link" href="/categories/arts-and-entertainment/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">Arts and Entertainment</span>
				
			</a>
		</li>
		<li class="menu__item">
			<a class="menu__link" href="/categories/health-and-medicine/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">Health and Medicine</span>
				
			</a>
		</li>
		<li class="menu__item">
			<a class="menu__link" href="/categories/science-and-technology/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">Science and Technology</span>
				
			</a>
		</li>
		<li class="menu__item">
			<a class="menu__link" href="/categories/sports/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">Sports</span>
				
			</a>
		</li>
		<li class="menu__item">
			<a class="menu__link" href="/categories/opinion/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">Opinion</span>
				
			</a>
		</li>
		<li class="menu__item">
			<a class="menu__link" href="/categories/parallel-universe-reports/">
				<i class='fa fa-heart'></i>
				<span class="menu__text">Parallel Universe Reports</span>
				
			</a>
		</li>
	</ul>
</nav>

	</div>
</header>
		<div class="wrapper flex">
			<div class="primary">
			
<main class="main" role="main">
	<article class="post">
		<header class="post__header">
			<h1 class="post__title">FDA grants traditional approval to Eisai/Biogen Alzheimer’s drug Leqembi</h1>
            
            <div class="author-link byline">By
  
  <a href="/staff/akira-rorschach">Akira Rorschach</a>
</div>
            
			<div>
<div class="meta__item-datetime meta__item">
	<svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0C7 0 1 6 1 14s6 14 14 14 14-6 14-14S23 0 15 0zm0 25C9 25 4 20 4 14S9 3 15 3s11 5 11 11-5 11-11 11zm1-18h-2v8.4l6.8 4.4L22 18l-6-3.8V7z"/></svg><time class="meta__text" datetime="2023-07-13T03:07:35-04:00">03:07 2023-07-13</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2l1 2h8v11h-16v-13z"/></svg><span class="meta__text"><a class="meta__link" href="/categories/health-and-medicine/" rel="category">Health and Medicine</a>
	</span>
</div></div>
			
		</header>
		
	<figure class="post__thumbnail thumbnail">
		
		<img class="thumbnail__image" src="/2023/health-and-medicine/leqembiProductPackagingShotMay2023.jpg" alt="FDA grants traditional approval to Eisai/Biogen Alzheimer’s drug Leqembi">
		
	</figure>
		<p> 
    <i> 
        Photo of Leqembi product packaging. EISAI/Handout 
        
        
    </i> 
</p>

<div class="content post__content clearfix">
			<p>July 12 (ZFJ) — The Food and Drug Administration granted traditional approval to Eisai and Biogen’s Leqembi (lecanemab-irmb) 100 mg/mL intravenous injection on July 6. It is the first Alzheimer’s drug to clear this regulatory hurdle and aims to slow the disease’s progression.</p>
<p>“Today’s action is the first verification that a drug targeting the underlying disease process of Alzheimer’s disease has shown clinical benefit in this devastating disease,” said Teresa Buracchio, acting director of the Office of Neuroscience in FDA’s Center for Drug Evaluation and Research.</p>
<p>Leqembi is a monoclonal antibody treatment that targets aggregated soluble and insoluble forms of amyloid beta (Aβ) protein. Monoclonal antibodies are lab-made proteins that can bind to certain targets in the body.</p>
<p>Alzheimer’s disease is an irreversible brain disorder that gradually destroys a patient’s memory, thinking skills, and ability to perform simple tasks. It affects over 6.5 million Americans.</p>
<p>The cause of Alzheimer’s remains unknown, but the disease is characterized by the formation of amyloid beta plaques and neurofibrillary tangles, which results in the loss of neurons, which transmit information in the nervous system. Current research suggests that removing these plaques can slow the disease’s progression.</p>
<p>The FDA first granted Leqembi accelerated approval on January 6, 2023. According to the medicine agency, this approval allows regulators to “approve drugs for serious conditions where there is an unmet medical need, based on clinical data demonstrating the drug’s effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients.”</p>
<p>As a condition of accelerated approval, the FDA required the pharmaceutical companies to conduct a phase 3 study to confirm Leqembi’s efficacy in slowing Alzheimer’s.</p>
<p>The study, <a href="https://clinicaltrials.gov/study/NCT03887455">Study 301 (Clarity AD)</a>, involved 1,795 patients and was double-blind and placebo-controlled. Patients were randomized in a 1:1 ratio to receive either a placebo or Leqembi. The study’s results were <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2212948">published in <em>The New England Journal of Medicine</em></a>.</p>
<p>The study found that Leqembi resulted in a statistically significant reduction of progression in the primary endpoint, the Clinical Dementia Rating-Sum of Boxes score, from baseline to 18 months. The CDR-SB score assesses cognition and function based on interviews with the patients. Higher scores reflect greater impairment.</p>
<p>The study also found statistically significant differences on all secondary endpoints, including the amount of amyloid beta plaques remaining, Alzheimer’s Disease Assessment Scale Cognitive Subscale 14 (ADAS-cog14), and Alzheimer’s Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL).</p>
<p><img src="/2023/health-and-medicine/leqembiEndpoints.jpeg" alt="Graphs showing primary and secondary endpoint results of the phase 3 study Study 301 (Clarity AD) concerning Leqembi&rsquo;s effectiveness. THE NEW ENGLAND JOURNAL OF MEDICINE/Graphic">
<em>Graphs showing primary and secondary endpoint results of the phase 3 study Study 301 (Clarity AD) concerning Leqembi&rsquo;s effectiveness. THE NEW ENGLAND JOURNAL OF MEDICINE/Graphic</em></p>
<p>Leqembi is meant for patients with mild cognitive impairment or mild dementia stage of Alzheimer’s. This population was studied in the clinical trial. There is no data on its safety or efficacy at earlier or later stages of the disease.</p>
<p>The most common adverse events from Leqembi use in the study were infusion-related reactions (26.4% who received lecanemab affected), ARIA (17.3%), ARIA-E (12.6%), headache (11.1%), and falls (10.4%). ARIA stands for amyloid-related imaging abnormalities and often presents with temporary brain swelling and small spots of bleeding. It can infrequently present with life-threatening brain edema (excess fluid accumulation) or fatal intracerebral hemorrhages.</p>
<p>Patients who are homozygous for (have two copies of) the ApoE ε4 allele (form of a gene) are more likely to have ARIA.</p>
<p>With these results, the eight members of the Peripheral and Central Nervous System Drugs Advisory Committee, an FDA panel of independent experts, voted in favor of approving the drug on June 9, 2023. The committee currently has three vacancies.</p>
<p>“Today marks a breakthrough in the treatment of Alzheimer’s disease, and we are proud to be at the forefront of ushering in a new era of advances for a disease that was previously considered untreatable,” said Biogen President and CEO Christopher A. Viehbacher.</p>
<p>The approval also means that Medicare will now cover Leqembi.</p>
<p>Patients enrolled in Medicare who are diagnosed with mild cognitive impairment or mild dementia, have documented evidence of amyloid-beta plaques, and have a physician participating in a qualifying registry are eligible for coverage, said the <a href="https://www.cms.gov/newsroom/press-releases/statement-broader-medicare-coverage-leqembi-available-following-fda-traditional-approval">Centers for Medicare and Medicaid Services</a>.</p>
<p>Leqembi will cost $26,500 per year. Eisai estimates out-of-pocket costs for patients to range from $0.00 to $14.50 per day, depending on one’s insurance.</p>
<p>Leqembi’s approval was granted to Eisai, the lead of the drug’s development and regulatory submissions. Eisai and Biogen both co-commercialize and co-promote it.</p>
<p>Leqembi’s approval in Japan, the European Union, China, Canada, Great Britain, and South Korea is pending.</p>
<p>One anti-amyloid antibody, Biogen’s Aduhelm (aducanumab), previously received accelerated approval from the FDA on June 7, 2021.</p>
<p>This decision was controversial because the independent nervous system drugs advisory committee overwhelmingly voted against doing so. Two phase 3 clinical trials were conducted for Aduhelm, one of which did demonstrate slower Alzheimer’s progression, and one of which did not support the drug’s effectiveness, although both studies showed it reduced amyloid plaque levels in patients.</p>
<p><a href="https://www.reuters.com/world/us/third-member-us-fda-advisory-panel-resigns-over-alzheimers-drug-approval-2021-06-10/">Three members of the advisory committee resigned in response to Aduhelm’s approval.</a></p>
<p><strong>References</strong></p>
<ul>
<li>U.S. Food and Drug Administration - FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval - <a href="https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval">https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval</a> (<a href="https://web.archive.org/web/20230713071045/https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval">ARCHIVE</a>)</li>
<li>U.S. Food and Drug Administration - FDA’s Decision to Approve New Treatment for Alzheimer’s Disease - <a href="https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease">https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease</a> (<a href="https://web.archive.org/web/20230713071222/https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease">ARCHIVE</a>)</li>
<li>Eisai - FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease - <a href="https://www.eisai.com/news/2023/news202349.html">https://www.eisai.com/news/2023/news202349.html</a> (<a href="https://web.archive.org/web/20230713071300/https://www.eisai.com/news/2023/news202349.html">ARCHIVE</a>)</li>
<li>The New England Journal of Medicine - Lecanemab in Early Alzheimer’s Disease - <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2212948">https://www.nejm.org/doi/full/10.1056/NEJMoa2212948</a> (<a href="https://web.archive.org/web/20230713071338/https://www.nejm.org/doi/full/10.1056/NEJMoa2212948">ARCHIVE</a>)</li>
<li>Centers for Medicare and Medicaid Services - Statement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval - <a href="https://www.cms.gov/newsroom/press-releases/statement-broader-medicare-coverage-leqembi-available-following-fda-traditional-approval">https://www.cms.gov/newsroom/press-releases/statement-broader-medicare-coverage-leqembi-available-following-fda-traditional-approval</a> (<a href="https://web.archive.org/web/20230713071512/https://www.cms.gov/newsroom/press-releases/statement-broader-medicare-coverage-leqembi-available-following-fda-traditional-approval">ARCHIVE</a>)</li>
<li>National Cancer Institute - monoclonal antibody - <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/monoclonal-antibody">https://www.cancer.gov/publications/dictionaries/cancer-terms/def/monoclonal-antibody</a> (<a href="https://web.archive.org/web/20230713071602/https://www.cancer.gov/publications/dictionaries/cancer-terms/def/monoclonal-antibody">ARCHIVE</a>)</li>
<li>ClinicalTrials.gov - ClinicalTrials.gov Glossary Terms - <a href="https://clinicaltrials.gov/study-basics/glossary">https://clinicaltrials.gov/study-basics/glossary</a> (<a href="https://web.archive.org/web/20230713071701/https://clinicaltrials.gov/study-basics/glossary">ARCHIVE</a>)</li>
<li>ClinicalTrials.gov - A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer&rsquo;s Disease (Clarity AD) - <a href="https://clinicaltrials.gov/study/NCT03887455">https://clinicaltrials.gov/study/NCT03887455</a> (<a href="https://web.archive.org/web/20230713071658/https://clinicaltrials.gov/study/NCT03887455">ARCHIVE</a>)</li>
</ul>

		</div>
		<footer class="post__footer">
			
<div class="post__tags tags clearfix">
	<svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M32 19c0 1-1 2-1 2L21 31s-1 1-2 1-2-1-2-1L2 16c-1-1-1.4-2-1.4-2S0 12.5 0 11V3C0 1.5.8.8.8.8S1.5 0 3 0h8c1.5 0 3 .6 3 .6S15 1 16 2l15 15s1 1 1 2zM7 10a3 3 0 1 0 0-6 3 3 0 0 0 0 6z"/></svg>
	<ul class="tags__list">
		<li class="tags__item">
			<a class="tags__link btn" href="/tags/leqembi/" rel="tag">Leqembi</a>
		</li>
		<li class="tags__item">
			<a class="tags__link btn" href="/tags/alzheimers-disease/" rel="tag">Alzheimer&#39;s disease</a>
		</li>
		<li class="tags__item">
			<a class="tags__link btn" href="/tags/eisai/" rel="tag">Eisai</a>
		</li>
		<li class="tags__item">
			<a class="tags__link btn" href="/tags/biogen/" rel="tag">Biogen</a>
		</li>
		<li class="tags__item">
			<a class="tags__link btn" href="/tags/u.s.-food-and-drug-administration/" rel="tag">U.S. Food and Drug Administration</a>
		</li>
		<li class="tags__item">
			<a class="tags__link btn" href="/tags/medicare/" rel="tag">Medicare</a>
		</li>
		<li class="tags__item">
			<a class="tags__link btn" href="/tags/the-new-england-journal-of-medicine/" rel="tag">The New England Journal of Medicine</a>
		</li>
	</ul>
</div>
		</footer>
	</article>
</main>


<nav class="pager flex">
	<div class="pager__item pager__item--prev">
		<a class="pager__link" href="/health-and-medicine/2024/readme/" rel="prev">
			<span class="pager__subtitle">«&thinsp;Previous</span>
			<p class="pager__title"></p>
		</a>
	</div>
	<div class="pager__item pager__item--next">
		<a class="pager__link" href="/health-and-medicine/2023/who-aspartame-possible-carcinogen-limited-evidence/" rel="next">
			<span class="pager__subtitle">Next&thinsp;»</span>
			<p class="pager__title">“Limited evidence” for aspartame as “possible carcinogen,” says WHO cancer agency</p>
		</a>
	</div>
</nav>


			</div>
			<aside class="sidebar"><div class="widget-search widget">
	<form class="widget-search__form" role="search" method="get" action="https://google.com/search">
		<input class="widget-search__field" type="search" placeholder="Search…" value="" name="q" aria-label="Search…">
		<input class="widget-search__submit" type="submit" value="Search">
		<input type="hidden" name="sitesearch" value="https://theZFJ.github.io/">
	</form>
</div>
<div class="widget-recent widget">
	<h4 class="widget__title">Recent Posts</h4>
	<div class="widget__content">
		<ul class="widget__list">
			<li class="widget__item"><a class="widget__link" href="/domestic-affairs/2024/edison-police-joseph-vincent-luistro-death/">Edison’s first Asian American police officer, Joseph Vincent Luistro, dies after battling ALS</a></li>
			<li class="widget__item"><a class="widget__link" href="/arts-and-entertainment/2024/matpat-game-theorists-youtube-retirement/">Not a Game Theory: MatPat announces upcoming retirement from YouTube</a></li>
			<li class="widget__item"><a class="widget__link" href="/arts-and-entertainment/2024/tom-scott-youtube-retirement/">Tom Scott indefinitely ends decade-long YouTube series</a></li>
			<li class="widget__item"><a class="widget__link" href="/domestic-affairs/2024/edison-police-private-van-driver-neglect-disabled-person/">Edison police charge van driver with leaving disabled person in vehicle overnight</a></li>
			<li class="widget__item"><a class="widget__link" href="/sports/2024/ghelsey-go-scores-thousandth-point-ehs-girls-basketball/">Ghelsey Go tops 1,000 points in girls&#39; basketball</a></li>
		</ul>
	</div>
</div>
<div class="widget-categories widget">
	<h4 class="widget__title">Categories</h4>
	<div class="widget__content">
		<ul class="widget__list">
			<li class="widget__item">
				<a class="widget__link" href="/categories/arts-and-entertainment/">Arts and Entertainment</a></li>
			<li class="widget__item">
				<a class="widget__link" href="/categories/business/">Business</a></li>
			<li class="widget__item">
				<a class="widget__link" href="/categories/domestic-affairs/">Domestic Affairs</a></li>
			<li class="widget__item">
				<a class="widget__link" href="/categories/foreign-affairs/">Foreign Affairs</a></li>
			<li class="widget__item">
				<a class="widget__link" href="/categories/health-and-medicine/">Health and Medicine</a></li>
			<li class="widget__item">
				<a class="widget__link" href="/categories/opinion/">Opinion</a></li>
			<li class="widget__item">
				<a class="widget__link" href="/categories/science-and-technology/">Science and Technology</a></li>
			<li class="widget__item">
				<a class="widget__link" href="/categories/sports/">Sports</a></li>
		</ul>
	</div>
</div>
<div class="widget-social widget">
	<h4 class="widget-social__title widget__title">Social</h4>
	<div class="widget-social__content widget__content">
		<div class="widget-social__item widget__item">
			<a class="widget-social__link widget__link btn" title="Twitter" rel="noopener noreferrer" href="https://twitter.com/AkiraRorschach" target="_blank">
				<svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5 0-78.8 35.3-78.8 78.8 0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3-6.7 11.6-10.6 25.2-10.6 39.6 0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1 0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4 0-12.6-.4-18.8-1.1 34.9 22.4 76.3 35.4 120.8 35.4 144.9 0 224.1-120 224.1-224.1 0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
				<span>Twitter</span>
			</a>
		</div>
		<div class="widget-social__item widget__item">
			<a class="widget-social__link widget__link btn" title="Instagram" rel="noopener noreferrer" href="https://www.instagram.com/zfjnews" target="_blank">
				<svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7 0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8 0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9 0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 1 0 0-84 42 42 0 0 0 0 84zm0 22.5a64.5 64.5 0 1 0 0-129 64.5 64.5 0 0 0 0 129z"/></svg>
				<span>Instagram</span>
			</a>
		</div>
		<div class="widget-social__item widget__item">
			<a class="widget-social__link widget__link btn" title="Email" href="mailto:alvin.wu@zfjnews.com">
				<svg class="widget-social__link-icon icon icon-mail" width="24" height="24" viewBox="0 0 416 288"><path d="m0 16v256 16h16 384 16v-16-256-16h-16-384-16zm347 16-139 92.5-139-92.5zm-148 125.5 9 5.5 9-5.5 167-111.5v210h-352v-210z"/></svg>
				<span>alvin.wu@zfjnews.com</span>
			</a>
		</div>

		
	</div>
</div>
</aside>
		</div>
		<footer class="footer">
	<div class="container footer__container flex">
		
		<div class="footer__copyright">
			&copy; 2024 The Zombie Fridge Journal.
			<span class="footer__copyright-credits">Generated with <a href="https://gohugo.io/" rel="nofollow noopener" target="_blank">Hugo</a> and <a href="https://github.com/Vimux/Mainroad/" rel="nofollow noopener" target="_blank">Mainroad</a> theme.</span>
		</div>
	</div>
</footer>
	</div>
<script async defer src="/js/menu.js"></script>
</body>
</html>